tetano
Editor, Senior Moderator
Eur J Med Res
. 2022 Feb 15;27(1):25.
doi: 10.1186/s40001-022-00655-6.
Major coagulation disorders and parameters in COVID-19 patients
Azadeh Teimury[SUP] 1 [/SUP], Mahshid Taheri Khameneh[SUP] 2 [/SUP], Elahe Mahmoodi Khaledi[SUP] 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), with a high prevalence rate, has rapidly infected millions of people around the world. Since viral infections can disrupt the coagulation and homeostasis cascades, various inflammatory and coagulation problems occur due to COVID-19 infection, similar to coronavirus epidemics in 2003 and 2004. According to multiple previous studies, in the present research, we reviewed the most commonly reported problems of COVID-19 patients, such as venous thromboembolism, pulmonary embolism, disseminated intravascular coagulation, etc. and investigated the causes in these patients. Coagulation and inflammatory markers, such as platelets and fibrinogen, C-reactive protein, lactate dehydrogenase, d-dimer, prothrombin time, etc., were also discussed, and the treatment options were briefly reviewed. In addition to coagulation treatments, regular examination of coagulation parameters and thrombotic complications can be helpful in the timely treatment of patients. Therefore, it is helpful to review the coagulation problems in COVID-19 patients. Although all mentioned problems and markers are important in COVID-19, some of them are more valuable in terms of diagnosis and prognosis.
Keywords: Anticoagulant therapies; COVID-19; Coagulation parameters; Coagulopathy; Thromboembolic events.
. 2022 Feb 15;27(1):25.
doi: 10.1186/s40001-022-00655-6.
Major coagulation disorders and parameters in COVID-19 patients
Azadeh Teimury[SUP] 1 [/SUP], Mahshid Taheri Khameneh[SUP] 2 [/SUP], Elahe Mahmoodi Khaledi[SUP] 3 [/SUP]
Affiliations
- PMID: 35168674
- DOI: 10.1186/s40001-022-00655-6
Abstract
Coronavirus disease 2019 (COVID-19), with a high prevalence rate, has rapidly infected millions of people around the world. Since viral infections can disrupt the coagulation and homeostasis cascades, various inflammatory and coagulation problems occur due to COVID-19 infection, similar to coronavirus epidemics in 2003 and 2004. According to multiple previous studies, in the present research, we reviewed the most commonly reported problems of COVID-19 patients, such as venous thromboembolism, pulmonary embolism, disseminated intravascular coagulation, etc. and investigated the causes in these patients. Coagulation and inflammatory markers, such as platelets and fibrinogen, C-reactive protein, lactate dehydrogenase, d-dimer, prothrombin time, etc., were also discussed, and the treatment options were briefly reviewed. In addition to coagulation treatments, regular examination of coagulation parameters and thrombotic complications can be helpful in the timely treatment of patients. Therefore, it is helpful to review the coagulation problems in COVID-19 patients. Although all mentioned problems and markers are important in COVID-19, some of them are more valuable in terms of diagnosis and prognosis.
Keywords: Anticoagulant therapies; COVID-19; Coagulation parameters; Coagulopathy; Thromboembolic events.